HOME > COMMENTARY
COMMENTARY
-
<Special Contribution> Happy New Year to Japanese Pharmaceutical Stocks!
January 12, 2004
-
<Special Contribution> Global Products Enhance Dominance in Japan with Local Products Confined to Niche Markets
January 12, 2004
-
November 10, 2003
-
<Special Contribution>
November 3, 2003
-
<Special Contribution>
September 1, 2003
-
Forecasting the Hypertensives Market: A Look Five Years Ahead Sugio Seko President, Pharma Marketing Survey Research Laboratory
August 11, 2003
-
June 9, 2003
-
May 12, 2003
-
March 24, 2003
-
January 20, 2003
-
< Special Contribution >
January 13, 2003
-
BARKER ON DRUGS
December 23, 2002
-
BARKER ON DRUGS (10)
November 18, 2002
-
BARKER ON DRUGS (9)
October 14, 2002
-
Commentary 2 articles
October 7, 2002
-
Barker on Drugs (8)
September 9, 2002
-
Barkers on Drugs (7)
July 29, 2002
-
BARKER ON DRUGS (6) Great Results, Shame about the Forecasts
June 24, 2002
-
BARKER ON DRUGS(5)
June 3, 2002
-
BARKER ON DRUGS(4)
April 22, 2002
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…